Delving into the Latest Updates on InnoPharma, Inc. with Synapse

概览

关联

6

项与 InnoPharma, Inc. 相关的临床试验

ACTRN12614000464662

/ Recruiting早期临床1期

A Single-Dose, Randomized, Open-Label, Crossover, Pilot, Comparative Bioavailability Study of Aprepitant 130 mg Injection (InnoPharma, Inc.), EMEND Registered Trademark 150 mg Injection (Merck Sharp & Dohme Corp.) and EMEND Registered Trademark 125 mg Capsules (Merck Sharp & Dohme Corp.) in Healthy Male and Female Volunteers under Fasting Conditions

开始日期2014-04-15

申办/合作机构

InnoPharma, Inc.

CTRI/2012/12/003216

/ Not yet recruitingN/A

A RANDOMISED, OPEN LABEL, BALANCED, SINGLE CENTRE, TWO PERIOD, TWO TREATMENT, TWO SEQUENCE, SINGLE DOSE, CROSSOVER, BIOEQUIVALENCE STUDY OF NISOLDIPINE 17 MG EXTENDED RELEASE TABLET TO SULARÂ® 17 MG EXTENDED RELEASE TABLET

开始日期2013-01-02

申办/合作机构

InnoPharma, Inc.

CTRI/2012/10/003074

/ Not yet recruitingN/A

A RANDOMISED, OPEN LABEL, BALANCED, SINGLE CENTRE, TWO PERIOD, TWOTREATMENT, TWO SEQUENCE, SINGLE DOSE, CROSSOVER, BIOEQUIVALENCE STUDY OFNISOLDIPINE 34 MG EXTENDED RELEASE TABLET TO SULARÂ® 34 MG EXTENDEDRELEASE TABLET

开始日期2012-12-28

申办/合作机构

InnoPharma, Inc.

100 项与 InnoPharma, Inc. 相关的临床结果

登录后查看更多信息

0 项与 InnoPharma, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 InnoPharma, Inc. 相关的药物交易

登录后查看更多信息

100 项与 InnoPharma, Inc. 相关的转化医学

登录后查看更多信息